Dosing for Liraglutide and Semaglutide
For liraglutide, start at 0.6 mg subcutaneously once daily, increase to 1.2 mg after 1 week, then to 1.8 mg (for diabetes) or 3.0 mg (for obesity) as tolerated; for semaglutide, start at 0.25 mg subcutaneously once weekly, escalate monthly to 0.5 mg, then 1.0 mg, and finally 2.4 mg (for obesity) or 1.0 mg (for diabetes with cardiovascular disease). 1, 2, 3
Liraglutide Dosing Regimen
For Type 2 Diabetes with Cardiovascular Disease
- Starting dose: 0.6 mg subcutaneously once daily
- Week 1 titration: Increase to 1.2 mg daily after 7 days
- Maintenance dose: 1.2-1.8 mg daily (titrate slowly based on tolerability)
- Maximum dose: 1.8 mg daily for glycemic control 1, 2, 4
For Obesity/Weight Management
- Starting dose: 0.6 mg subcutaneously once daily
- Weekly titration schedule:
Key point: The 3.0 mg dose is FDA-approved specifically for chronic weight management in patients ≥12 years with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with weight-related comorbidities 5.
Semaglutide Dosing Regimen
For Type 2 Diabetes
- Starting dose: 0.25 mg subcutaneously once weekly
- Month 1: 0.25 mg weekly (first 4 weeks)
- Month 2: 0.5 mg weekly
- Maintenance: 0.5-1.0 mg weekly
- Maximum: 2.0 mg weekly if additional glycemic control needed 1, 2
For Obesity/Weight Management and Cardiovascular Risk Reduction
- Starting dose: 0.25 mg subcutaneously once weekly
- Monthly titration schedule:
Critical consideration: The 2.4 mg weekly dose is FDA-approved for obesity treatment and has recently been approved for secondary cardiovascular risk reduction in patients with established cardiovascular disease and obesity (even without diabetes) 5.
Administration Details
Liraglutide
- Route: Subcutaneous injection
- Frequency: Once daily at any time of day, independent of meals
- Injection sites: Abdomen, thigh, or upper arm (rotate sites) 6
- Half-life: 13 hours 6
Semaglutide
- Route: Subcutaneous injection
- Frequency: Once weekly at any time of day, independent of meals
- Injection sites: Abdomen, thigh, or upper arm
- Half-life: 183 hours (approximately 1 week) 5
Renal Dosing Considerations
Both liraglutide and semaglutide require no dose adjustment for renal impairment, including in patients with chronic kidney disease. 1, 7
- Liraglutide: No dose adjustment required for any level of renal function, though data in end-stage renal disease are limited 2, 4, 7
- Semaglutide: No dose adjustment required for any level of renal function 1, 7
This is a significant advantage over some other diabetes medications that require dose reduction or are contraindicated in advanced kidney disease 7.
Titration Strategy and Tolerability
Slow dose escalation is essential to minimize gastrointestinal adverse effects (nausea, vomiting, diarrhea), which are the most common side effects. 3
If Doses Are Missed
- ≤2 consecutive doses missed: Resume at the same dose if previously well-tolerated
- >2 consecutive doses missed: Consider lowering the next dose
- ≥3 consecutive doses missed: Restart the titration schedule 3
Submaximal Dosing
Some patients achieve adequate glycemic control and weight loss at submaximal doses (e.g., liraglutide 1.2 mg or semaglutide 1.0 mg) and can continue long-term at these doses without further escalation 3.
Common Pitfalls to Avoid
- Rushing titration: Rapid dose escalation significantly increases gastrointestinal side effects and treatment discontinuation 3, 8
- Not counseling on transient nausea: Most nausea is mild-to-moderate and resolves within weeks; patients should be prepared for this 9, 10
- Combining with other GLP-1 RAs or DPP-4 inhibitors: Never use liraglutide or semaglutide with other incretin-based therapies 3
- Ignoring hypoglycemia risk with sulfonylureas/insulin: Reduce doses of these agents when initiating GLP-1 RAs to prevent hypoglycemia 2, 3
- Discontinuing before surgical procedures: Consider stopping GLP-1 RAs before elective surgery due to delayed gastric emptying 3